Akums Drugs & Pharmaceuticals Ltd Q1 FY26 Earnings Analysis

- **Trade Generics:** Revenue has declined from INR 500+ crores in FY'22 to around INR 100 crores recently; business is being consolidated focusing on profitable segments with no forecast for large growth. - **Domestic Formulations:** Targeting double-digit top-line growth, higher than overall Indian pharma market growth of around 8-9%. - **CDMO Business:** Expecting at least 20% year-on-year growth in current export and CDMO business. Volume growth targeted in single high digits (~9% QoQ currently), with revenues dependent on volatile API prices. - **Export Business:** Base branded export business expected to grow at high double digits (~20%+) over next 2-3 years. - **API Business:** Planning ~10% volume growth but revenues and profits dependent on Cephalosporin prices. Losses targeted to reduce but breakeven likely only by FY '27. - **Capacity Planning:** Capacity utilization currently ~31-38%, with plans to enhance production for growth in oral solids and injectables.

- **Revenue Growth**: Targeting double-digit top line growth in domestic formulations, higher than overall Indian pharma market; export business expected to grow at around 20% in next 2-3 years; CDMO business volume growth anticipated at single high digit (~9-15%). - **API Business**: Losses expected to significantly reduce, targeting breakeven or minimal losses by FY '27, with revenue growth around 10-15%. - **Trade Generics**: Business being consolidated due to high working capital and low profitability; future size expected to shrink but maintain profitable portions. - **Margins**: CDMO margins expected to be stable around 15-20%; overall company margin profile to improve as loss-making segments reduce losses. - **Profitability**: EBITDA losses in API and trade generics expected to decline; overall margin and EBITDA expected to improve with strategic focus on profitable segments. - **EPS**: With growth and margin expansion, earnings per share are expected to improve gradually aligned with business consolidation and expansion plans.

- FY '26 capex is estimated around INR 300 crores, split between maintenance and growth capex. - Growth capex includes investments in Jammu, liquid oral lines for the European business, oncology, steroids, and new dosage forms. - EUR 20 million (approx. INR 160+ crores) planned for plant upgrades and dossier development to meet European GMP standards for a large 6-year European contract. - New product facility being set up at Baddi 1 (A 11) for serving European markets. - Strategy includes adding capacity with foresight of 24 months due to plant validation timelines. - Capacity expansions are spread across dosage forms, including injectables, oral solids, oral liquids, oncologics, and steroids. - M&A opportunities actively explored, primarily in CDMO and export businesses, focusing on profitable and synergistic entities. - The INR 1,000+ crores cash on books is partly earmarked but can be used for strategic investments or acquisitions.

- The transcript does not mention any current or planned fundraising through debt or equity. - The company has a strong cash surplus of INR1,520 crores, including INR950 crores received as part payment for a European contract. - They also have an overdraft (OD) facility on fixed deposits, indicating access to short-term credit if needed. - Management appears focused on using available cash and possibly M&A opportunities without immediate plans for additional fundraising. - The emphasis is on investing in capex for growth (INR300 crore planned for FY26) funded largely from internal resources. - No explicit mention of launching new equity or debt issuance was made during the call.

- Akums Drugs & Pharmaceuticals has a significant contract in Europe valued at EUR100 million (~INR950 crores part payment received on April 9, 2025). - This contract is structured as a 6-year deal, expected to generate roughly INR300-350 crores in annual revenue. - The European contract marks entry into about 20 countries. - The business related to this contract falls under the CDMO segment, targeting similar margins (approximately 15%-20%). - For the base export branded business excluding the large European contract, the company expects high double-digit (around 20%) growth over the next 2 to 3 years. - No specific mention of other pending orderbooks or backlog figures was made.